Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Exocrine Pancreatic Dysfunction in Type 1 Diabetes
NCT ID: NCT05385211
Last Updated: 2023-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2022-04-30
2023-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetics of Insulin and Incretins in Cystic Fibrosis
NCT01852448
Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)
NCT07102043
Identification of Dysglycemia With Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis
NCT05099939
Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor
NCT03512119
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
NCT06350149
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patient data will then be separated into two groups based the presence or absence of exocrine pancreatic insufficiency (EPI). EPI will be defined based on the levels of pancreatic enzymes (Amylase; lipase; and trypsinogen). As the prevalence of EPI in people living with type 1 diabetes (PWT1D) is \~50%, we expect roughly the same number of individuals into both groups (with or without EPI).
Variables :
Subject data (age, gender, duration of diabetes, age at diagnostic, etc.) will be collected.
Glucose variation will be assessed with a continuous glucose monitoring system for 1 month. Briefly we will collect the number and severity of hyperglycemic events, average glucose levels, glycemic variability, etc..
From collected peripheral blood mononuclear cells (PBMCs) we will quantify CFTR function and level of expression, as well as identify CFTR variants by next generation sequencing.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People living with type 1 diabetes
Participants will be separated into two groups based on the levels of their exocrine pancreatic enzymes levels.
Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency
Blood samplings; Glucose monitoring; CFTR variants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency
Blood samplings; Glucose monitoring; CFTR variants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Living in Montreal
Exclusion Criteria
* Use of corticosteroid
* Use of medication known to have a relevant impact on glycemic control.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Juvenile Diabetes Research Foundation
OTHER
Institut de Recherches Cliniques de Montreal
OTHER
Ciusss de L'Est de l'Île de Montréal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sylvie Lesage
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sylvie Lesage, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Ciusss de L'Est de l'Île de Montréal
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1-INO-2022-1126-A-N
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.